Retatrutide (30mg)

Retatrutide, also called Reta, is a synthetic peptide with activity at GLP-1, GIP and glucagon receptors. This listing is for a 30mg lyophilised vial for in-vitro laboratory research. Milligrams describe the amount in the vial, not a dose or solution concentration.

The current listed vial quantities and prices are:
Retatrutide (10mg): $144.99 per vial, approximately $14.50 per mg (In Stock).
Retatrutide (15mg): $179.99 per vial, approximately $12.00 per mg (Out of Stock).
Retatrutide (20mg): $229.99 per vial, approximately $11.50 per mg (In Stock).
Retatrutide (30mg): $349.99 per vial, approximately $11.67 per mg (In Stock).
Retatrutide (60mg): $549.99 per vial, approximately $9.17 per mg (In Stock).
Milligrams describe the listed amount per vial. They do not describe the concentration of a prepared solution or a dosing schedule. Check each product's specification and published batch report when comparing formats.

Semaglutide targets GLP-1 receptors; tirzepatide targets GIP and GLP-1; Retatrutide adds glucagon-receptor activity. These are different compounds. The 2023 Retatrutide obesity trial used placebo as its comparator, so its results do not establish superiority over the other two medicines.

Retatrutide is commonly shortened to Reta or Reta peptide. LY3437943 is its research identifier. Check the compound name and milligrams per vial when comparing listings.

As checked on 15 September 2026, the TGA states that Retatrutide has not been approved. Lilly describes it as investigational and says public release depends on clinical trials and regulatory review; no Australian release date is confirmed in that guidance. This listing supplies a lyophilised laboratory research vial, not an approved pharmacy medicine or compounded prescription product. Current research-product stock is shown on this page.

Retatrutide activates GLP-1, GIP and glucagon receptors. This triple-receptor profile is studied in metabolic signalling research. Receptor activity alone does not establish a clinical benefit or a safe human-use protocol. See the original receptor research.

The 2023 Phase 2 obesity study compared Retatrutide with placebo. It does not validate this 30mg research vial or establish superiority to semaglutide or tirzepatide. See the Retatrutide 10mg research overview for the study population and evidence limits.

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a general peptide reconstitution overview see our complete peptide reconstitution guide.

Store lyophilized Retatrutide (30mg) vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

Aussie Peptides lists Retatrutide 30mg for in-vitro laboratory research with domestic Australian dispatch. Check this page for current stock and ordering options, and the CoA library for published reports for the specific product. A research listing is not an approved medicine supply route.

Retatrutide (30mg) is priced at $349.99 per vial, which works out to approximately $11.67 per milligram at Aussie Peptides.